VerityRank
Mycronic AB
Brand & Manufacturer VerifiedSweden

Mycronic AB

Mycronic

Mycronic may be smaller than its Japanese and American rivals, but the Swedish specialist holds near-monopoly positions in two niches that matter enormously to advanced electronics manufacturers. In 2025 the company delivered net sales of SEK 7.938 billion (about USD 750 million), up 12%, with an EBIT margin of 24% — among the highest in the equipment industry — and set a record quarterly operating profit in Q1 2026, prompting management to raise its 2026 guidance to SEK 8.75 billion. With 2,673 employees and operations in nearly 50 countries, Mycronic dominates solder paste jet printing (a stencil-free technology essential for aerospace, medical, and defense boards) and the high-mix/low-volume placement segment.

Strengths: The MYPro series flexible mounters and jet printers command premium pricing in high-mix/low-volume production, where changeover speed matters more than raw CPH. The jet printing monopoly position — no stencil required — makes Mycronic effectively indispensable for complex, high-reliability boards in aerospace, medical, and military applications. The 2025 acquisition of German test-probe maker ETZ extends its PCB test portfolio, while the GenI system applies generative AI to AOI programming, a breakthrough that could reshape inspection workflows. The new Thailand factory diversifies production away from single-region risk.

Weaknesses: Management indefinitely shelved the IPO of its Axxon subsidiary on the Chinese stock exchange, citing the depressed Chinese capital market and limiting access to local funding. The China market remains soft, weighing on the High Volume segment. With its reliance on specialized niches, Mycronic's growth is tied to the fortunes of high-mix electronics manufacturers, which are more sensitive to economic cycles than high-volume consumer lines.
Read More
SwedenFounded 19892,673 employeesSEK$7.9 B net sales…Täby HQ , Shenzhen , new… / 100
Listed onSTOMYCRMYCR
Last updated: 2026-11-18 23:30 ET·By VerityRank Research Team·Methodology

Listed market data

MYCR · STO · weeklyHistory →
Market cap
$6.1 B
Share price
SEK 301.60
1Y change
+33.8%
Recent change
+1.5%

11-18 → 11-19

Since first close
+129.8%

from 2000

Revenue (TTM)
$950 M
Revenue FY 2026 · updated 2026-11-18 23:30 ETSource ↗

Financial history

Full market history
SEK 0$0SEK 100$2.0 BSEK 200$4.0 BSEK 300$6.0 BSEK 400$8.0 B2025-122026-012026-022026-032026-042026-052026-062026-072026-082026-092026-102026-11
MonthCloseMarket capChange
  • 2026-11SEK 301.60$6.1 B+1.1%
  • 2026-10SEK 298.20$5.7 B0.0%
  • 2026-09SEK 298.20$5.7 B-11.8%
  • 2026-08SEK 338.20$6.4 B+3.8%
  • 2026-07SEK 325.80$6.2 B+3.8%
  • 2026-06SEK 313.80$6 B-2.3%
  • 2026-05SEK 321.20$6.1 B+7.8%
  • 2026-04SEK 298.00$5.7 B+3.1%
  • 2026-03SEK 289.00$5.5 B+32.6%
  • 2026-02SEK 218.00$4.2 B+6.2%
  • 2026-01SEK 205.30$3.9 B-0.2%
  • 2025-12SEK 205.80$3.9 B—
Monthly closes · 2025-12 – 2026-11 · Full market history

Ownership & Control

Latest available filings
Controlling entity
Publicly held — no controlling shareholder disclosed
Company type
Brand & Manufacturer
Insiders
0.20%
Institutions
79.11%(158 holders)
Free float
79.27%

Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.

In the press

All coverage →5 latest headlines1
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.

Mycronic AB is a Swedish manufacturer of electronics assembly equipment headquartered in Täby, near Stockholm, and listed on Nasdaq Stockholm (MYCR). Founded in 1989, the company generated SEK 7.938 billion (approximately USD 750 million) in 2025 net sales, up 12% year-on-year, with operating profit (EBIT) of SEK 1.940 billion and a 24% margin. Employing 2,673 people and operating through direct sales and agents in nearly 50 countries, Mycronic holds dominant positions in solder paste jet printing and high-mix/low-volume placement.

Business Overview

Mycronic's electronics assembly business splits into two roughly equal halves. PCB Assembly Solutions (22% of group sales) centers on the MYPro series flexible placement machines and the pioneering jet printing technology, which deposits solder paste without stencils — an approach ideally suited to complex, low-volume, high-reliability boards used in aerospace, medical, defense, and communications equipment. High Volume (22% of sales) is anchored by the Chinese subsidiary Axxon, which manufactures high-speed dispensing equipment for consumer electronics and automotive production. The remainder of the group includes mask writers for display and semiconductor manufacturing.

2025 was a year of strong performance and strategic expansion. Net sales grew 12% to SEK 7.938 billion, driven by AI-related applications and global technology investment, while the operating margin held at a sector-leading 24%. In Q1 2026 the company recorded its highest quarterly operating profit ever, prompting the board to raise full-year 2026 guidance to SEK 8.75 billion. Operationally, Mycronic completed the relocation and expansion of its Kista production line, commissioned a new factory in Thailand, and completed the acquisition of German test-probe manufacturer ETZ to broaden its PCB test portfolio.

Core Strengths

Mycronic's deepest competitive advantage is its jet printing technology. Because jet printing requires no stencils, it eliminates setup cost and lead time for complex boards, making it effectively the only viable solution for many aerospace, medical, and military applications — giving Mycronic pricing power and customer stickiness that placement-machine vendors cannot replicate. In the high-mix/low-volume placement segment, the MYPro series' rapid changeover capability similarly commands a premium, as factories increasingly shift toward flexible production.

Innovation keeps the moat fresh. The GenI system, unveiled in 2025-2026, applies generative AI to AOI programming, potentially slashing the engineering effort required to set up inspection processes — a breakthrough that could accelerate adoption across the entire inspection market. The ETZ acquisition adds PCB testing capability, moving Mycronic further along the line toward full-process solutions. Operationally, the Thailand factory and Swedish expansion diversify geographic production risk, while the 24% EBIT margin provides ample self-funding capacity.

Risks & Outlook

The principal near-term risk is China. Management indefinitely shelved the planned IPO of the Axxon subsidiary on the Chinese stock exchange, citing the depressed local capital market, which limits funding flexibility and signals softness in the Chinese electronics sector. The High Volume segment's growth is consequently more dependent on global consumer electronics cycles than on Chinese expansion. As a specialist, Mycronic also carries concentration risk: its fortunes track the high-mix electronics niche, which is more sensitive to macroeconomic cycles than mass-production lines.

The outlook, however, is strongly positive. Record Q1 2026 results and upgraded guidance reflect accelerating AI-driven demand across its customer base, while the GenI AI inspection system and ETZ test portfolio open new growth vectors. The company's 24% operating margin, strong balance sheet, and leadership in two defensible niches position it well to compound growth for years. VerityRank Score of 85/100

Quick Facts

Headquarters

Nytorpsvägen 9, Box 3141, 183 03 Täby, Sweden

Founded

1989

Employees

2,673 employees

Revenue

SEK$7.9 B net sales (2025, ~USD$750 M), +12% YoY; EBIT margin 24%

Market cap

$6.1 B

Factories

Täby HQ (Sweden), Shenzhen (Axxon, China), new Thailand factory (2025)

Presence

Direct sales and agent network in nearly 50 countries
Categories

19 categories · scroll for more

Related

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website Nasdaq Stockholm: MYCR , Mycronic Year-end Report 2025 (official)
Mycronic Record Q1 2026 (I-Connect007)
Mycronic Official Website